GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ZELTIQ Aesthetics Inc (NAS:ZLTQ) » Definitions » Operating Income

ZELTIQ Aesthetics (ZELTIQ Aesthetics) Operating Income : $13.2 Mil (TTM As of Dec. 2016)


View and export this data going back to 2011. Start your Free Trial

What is ZELTIQ Aesthetics Operating Income?

ZELTIQ Aesthetics's Operating Income for the three months ended in Dec. 2016 was $16.3 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2016 was $13.2 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. ZELTIQ Aesthetics's Operating Income for the three months ended in Dec. 2016 was $16.3 Mil. ZELTIQ Aesthetics's Revenue for the three months ended in Dec. 2016 was $105.1 Mil. Therefore, ZELTIQ Aesthetics's Operating Margin % for the quarter that ended in Dec. 2016 was 15.47%.

ZELTIQ Aesthetics's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. ZELTIQ Aesthetics's annualized ROC % for the quarter that ended in Dec. 2016 was 50.38%. ZELTIQ Aesthetics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2016 was 190.37%.


ZELTIQ Aesthetics Operating Income Historical Data

The historical data trend for ZELTIQ Aesthetics's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZELTIQ Aesthetics Operating Income Chart

ZELTIQ Aesthetics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Operating Income
Get a 7-Day Free Trial -30.04 -19.35 2.12 3.69 13.22

ZELTIQ Aesthetics Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.80 -11.16 -3.53 11.66 16.26

ZELTIQ Aesthetics Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ZELTIQ Aesthetics  (NAS:ZLTQ) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

ZELTIQ Aesthetics's annualized ROC % for the quarter that ended in Dec. 2016 is calculated as:

ROC % (Q: Dec. 2016 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2016 ) + Invested Capital (Q: Dec. 2016 ))/ count )
=65.032 * ( 1 - 32.87% )/( (79.012 + 94.31)/ 2 )
=43.6559816/86.661
=50.38 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2016) data.

2. Joel Greenblatt's definition of Return on Capital:

ZELTIQ Aesthetics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2016 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2016 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2016  Q: Dec. 2016
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=65.032/( ( (9.637 + max(10.456, 0)) + (12.14 + max(36.087, 0)) )/ 2 )
=65.032/( ( 20.093 + 48.227 )/ 2 )
=65.032/34.16
=190.37 %

where Working Capital is:

Working Capital(Q: Sep. 2016 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(40.348 + 32.246 + 10.286) - (53.716 + 18.708 + 0)
=10.456

Working Capital(Q: Dec. 2016 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(55.269 + 37.963 + 15.614) - (63.617 + 9.142 + 0)
=36.087

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2016) EBIT data.

3. Operating Income is also linked to Operating Margin %:

ZELTIQ Aesthetics's Operating Margin % for the quarter that ended in Dec. 2016 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2016 )/Revenue (Q: Dec. 2016 )
=16.258/105.11
=15.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


ZELTIQ Aesthetics Operating Income Related Terms

Thank you for viewing the detailed overview of ZELTIQ Aesthetics's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


ZELTIQ Aesthetics (ZELTIQ Aesthetics) Business Description

Traded in Other Exchanges
N/A
Address
ZELTIQ Aesthetics Inc was incorporated in Delaware in March 2005 as Juniper Medical, Inc. In July 2007, it changed its name to ZELTIQ Aesthetics, Inc. ZELTIQ Aesthetics, Inc. is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled cooling technology platform. Its first commercial product, the CoolSculpting system, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues.
Executives
Todd Erik Zavodnick officer: President, International C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Bradley Hauser officer: SVP, Research and Development C/O ZELTIQ AESTHETICS, INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
Danika R Harrison officer: SVP of Global Marketing C/O ZELTIQ AESTHETICS, INC. 4410 ROSEWOOD DRIVE PLEASANTON CA 94588
Mark J Foley director, officer: President and CEO ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Taylor C. Harris officer: SVP & Chief Financial Officer 6035 STONERIDGE DRIVE, PLEASANTON CA 94588
Kevin C Oboyle director 5964 LA PLACE COURT, CARLSBAD CA 92008
Mary Fisher director C/O ACORDA THERAPEUTICS, INC., 15 SKYLINE DRIVE, HAWTHORNE NY 10532
D Keith Grossman director
Andrew N Schiff director, 10 percent owner PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Keith J Sullivan officer: CCO, President, North America C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Patrick F. Williams officer: SVP & CFO C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
Leonard C Debenedictis officer: Chief Technical Officer C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Bryan E Roberts director C/O VENROCK ASSOCIATES, 2494 SAND HILL ROAD STE 200, MENLO PARK CA 94025
Jean George director CRITICAL THERAPEUTICS INC, 60 WESTVIEW STREET, LEXINGTON MA 02421
Aisling Capital Iii Lp 10 percent owner 888 Seventh Avenue, 30th Fl, New York NY 10106

ZELTIQ Aesthetics (ZELTIQ Aesthetics) Headlines

No Headlines